Long-term safety and efficacy of etanercept in the treatment of psoriasis;Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis

Actas Dermo-Sifiliograficas

Volumn 101, Issue 1, 2010, Pages 47-53

  Zaragoza, V ^a   Perez A ^a   Sanchez J L ^a   Oliver, V ^a   Martinez L ^a   Alegre, V ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Efficacy; Etanercept; Long term treatment; Safety

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN; METHOTREXATE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PHOTOTHERAPY; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR; VOMITING;

EID: 74149093801     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(10)70579-5     Document Type: Article

References (21)

1. Ferrandiz C, Bordas X, García-Patos V. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001;15:20-23.
2. Herrera E., and Habicheyn S. Eficacia clínica del etanercept en psoriasis y artritis psoriásica. Actas Dermosifiliogr 96 (2005) 10-24
3. Romero-Maté A., García-Donoso C., and Córdoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic artritis: An updated review. Am J Clin Dermatol 8 (2007) 143-155
4. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
5. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 356 (2000) 385-390
6. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 3 (2003) 2014-2022
7. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., et al. Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 1 (2005) 1304-1312
8. ®. España; 2005
9. Boehncke W.H., Brasie R.A., Barker J., Chimenti S., Daudén E., de Rie M., et al. European Dermatology Expert Group. Recommendations for the use of etanercept in psoriasis: A European dermatology expert group consensus. JEADV 20 (2006) 988-998
10. Papp K.A. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 298 (2006) 7-15
11. Krueger G.G., Elewski B., Papp K.A., Wang A., Zitnik R., and Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 54 (2006) S112-S119
12. th Congress of the European Academy of Dermatology and Venereology. Rhodes; 2006.
13. th Congress of the European Academy of Dermatology and Venereology. Rhodes: 2006.
14. th Annual Meeting of the American Academy of Dermatology. San Francisco (CA): 2006.
15. th Annual Meeting of the American Academy of Dermatology. San Francisco (CA): 2006.
16. th Congress of the European Academy of Dermatology and Venereology. Rhodes: 2006.
17. th Annual Meeting of the American Academy of Dermatology. San Francisco (CA): 2006.
18. Gamo R., and López-Estebaranz J.L. Terapia biológica y psoriasis. Actas Dermosifiliogr 97 (2006) 1-17
19. Martín B., et al. Etanercept en la psoriasis. Experiencia clínica. Actas Dermosifiliogr 9 (2008) 540-545
20. rd Annual Meeting of the American Academy of Dermatology. New Orleans (LA): 2007.
21. th Annual Meeting of the American Academy of Dermatology. Washington, DC: 2007.